Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
Preliminary findings to be shared from Cohort C (active brain metastases) of the REZILIENT2 trial of zipalertinib in patients with exon 20 insertion (ex20ins) or other uncommon mutation epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) PRINCETON, N.J., July 25, 2025 /PRNewswire/ — Taiho Oncology, Inc., a company developing and commercializing novel treatments for







